J Cancer 2016; 7(10):1317-1327. doi:10.7150/jca.15157

Research Paper

Multi-target siRNA: Therapeutic Strategy for Hepatocellular Carcinoma

Tiejun Li1,2,3, Yuwen Xue1, Guilan Wang1, Tingting Gu1, Yunlong Li1, York Yuanyuan Zhu2,3✉, Li Chen1✉

1. Department of Pathological Anatomy, Nantong University, Nantong, China;
2. Small RNA Technology and Application Institute, Nantong University, Nantong, China;
3. Biomics Biotechnologies Co., Ltd., Nantong, China.


Multiple targets RNAi strategy is a preferred way to treat multigenic diseases, especially cancers. In the study, multi-target siRNAs were designed to inhibit NET-1, EMS1 and VEGF genes in hepatocellular carcinoma (HCC) cells. And multi-target siRNAs showed better silencing effects on NET-1, EMS1 and VEGF, compared with single target siRNA. Moreover, multi-target siRNA showed greater suppression effects on proliferation, migration, invasion, angiogenesis and induced apoptosis in HCC cells. The results suggested that multi-target siRNA might be a preferred strategy for cancer therapy and NET-1, EMS1 and VEGF could be effective targets for HCC treatments.

Keywords: multi-target siRNA, hepatocellular carcinoma (HCC), NET-1, EMS1, VEGF.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Li T, Xue Y, Wang G, Gu T, Li Y, Zhu YY, Chen L. Multi-target siRNA: Therapeutic Strategy for Hepatocellular Carcinoma. J Cancer 2016; 7(10):1317-1327. doi:10.7150/jca.15157. Available from http://www.jcancer.org/v07p1317.htm